Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH
NCT04927936Unknown
- Sponsor
- Erasmus MC
- Start
- Jun 2021
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Randomised, single-blind trial of Ad26.COV2.S and elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Erasmus MC. Primary endpoint: Determination of antibodies by a quantitative IgG assay (LIAISON SARS-CoV-2 TrimericS IgG essay) at 28 days. Status: unknown.
02
Drugs
Ad26.COV2.Selasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04927936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927936.